Information Provided By:
Fly News Breaks for July 26, 2017
BIIB
Jul 26, 2017 | 08:51 EDT
Bernstein analyst Aaron Gal says that all of Biogen's key drugs had high prescribing rates last quarter. The analyst says that concerns about the company's Spinraza drug are misplaced as it did well last quarter and is getting better coverage from payers. He thinks that opportunities in neurology justify the company's investment in this area. Gal keeps a $310 price target and an Outperform rating on the shares.
News For BIIB From the Last 2 Days
There are no results for your query BIIB